NSCLC, Stage III

26 registered clinical trials studyying NSCLC, Stage III — 10 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectab NCT07410975	Shanghai Pulmonary Hospital, Shanghai, China	Phase 2
Not Yet Recruiting	Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC NCT07235306	Shanghai Pulmonary Hospital, Shanghai, China	Phase 2
Recruiting	PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study NCT06945484	University of Utah	N/A
Recruiting	Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC NCT06552234	Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer	Phase 2
Withdrawn	Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab NCT05757843	Indiana University	Phase 2
Recruiting	A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Adva NCT06467383	MSD Italia S.r.l.	—
Withdrawn	Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer NCT05718297	ETOP IBCSG Partners Foundation	Phase 2
Recruiting	A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cance NCT06512207	Jinzhou Medical University	N/A
Unknown	Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC NCT05611879	Beijing Tsinghua Chang Gung Hospital	Phase 2
Completed	A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemorad NCT05386888	Genfleet Therapeutics (Shanghai) Inc.	Phase 2
Recruiting	Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Canc NCT05344209	Vestre Viken Hospital Trust	Phase 2
Unknown	Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities NCT05311709	Vestre Viken Hospital Trust	Phase 2
Unknown	SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC NCT05177497	Shanghai Chest Hospital	Phase 2
Unknown	Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC. NCT05128630	Fondazione IRCCS Policlinico San Matteo di Pavia	Phase 2
Recruiting	Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NCT04585490	Maximilian Diehn	Phase 3
Unknown	Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC NCT04952168	Yuan Chen	Phase 2
Recruiting	Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patien NCT04680377	Jun Zhang, MD, PhD	—
Unknown	Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize NCT05027165	LMU Klinikum	—
Recruiting	Lung Cancer Registry NCT04654364	Arbeitsgemeinschaft medikamentoese Tumortherapie	—
Completed	A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China NCT04830826	The First Affiliated Hospital of Guangzhou Medical University	—
Completed	Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy NCT04351256	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Phase 2
Active Not Recruiting	Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study NCT04392505	Oslo University Hospital	Phase 2
Unknown	Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunot NCT04202809	University Hospital, Essen	Phase 2
Active Not Recruiting	Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small NCT03999710	Memorial Sloan Kettering Cancer Center	Phase 2
Unknown	The Role of Microbiota on the Development of Lung Cancer NCT03454685	Xiaorong Dong	—
Withdrawn	To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NCT03130829	Hi-Q Marine Biotech International, Ltd.	N/A